Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
Equipping Healthcare Professionals with the Necessary Tools for Improving Care in Ovarian Cancer
Choose from the criteria below to find an activity that fits you best.
This activity will improve the knowledge and competence of pharmacists about the management of anticoagulant-related bleeding, including recent guideline updates, selecting appropriate reversal agents and dosing strategies. Experts will discuss clinical data regarding the efficacy and safety outcomes of reversal agents for oral anticoagulants, and strategies to address formulary concerns, including access to reversal agents, streamlining administration, waste prevention, and institutional policy development, to improve patient care.
The target audience for this activity includes pharmacists, including clinical and health-system, ambulatory care, and community pharmacists, who care for patients with anticoagulant-related major bleeding. In addition, the target audience includes pharmacy directors, chief pharmacy officers, and other stakeholders in health-system pharmacy. At the completion of this activity, the participant will be able to:
Tyree H. Kiser, PharmD, FCCM, FCCP, BCCCP, BCPS
Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Critical Care Pharmacy Specialist, Department of Pharmacy
University of Colorado Hospital
Charles E. “Kurt” Mahan, PharmD, PhC, FASHP, FCCP
Adjunct Associate Professor, Pharmacy
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
Release Date: December 30, 2021
Expiration Date: December 30, 2022
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-21-279-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Tyree Kiser has disclosed that he has no conflicts of interest to report. Kurt Mahan has disclosed that he has performed contracted research, received consulting fees and fees for non-CME/CE services from Portola/Alexion/Astra Zeneca; received consulting fees and fees for non-CME/CE services from Janssen; received fees for non-CME/CE services from BMS/Pfizer; received consulting fees from Western Sky Community Care Healthplan Pharmacy and Therapeutics Committee.
This activity is supported by an educational grant from Alexion, AstraZeneca Rare Disease.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.